Quotables
"The idea that cavalry will be replaced by these iron coaches is absurd. It is little short of treasonous."
Aide-de-camp to Field Marshal Haig ; At a tank demonstration, 1916
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110288302 | Catalyst Coated Honeycomb Substrates and Methods of Using Them An essentially nonporous honeycomb substrate having greater than 900 cells per square inch and with a catalyst coating having a thickness less than 1 micron. The coated essentially nonporous honeycomb may be used, for example, for gas phase reactions.... | 11/24/2011 |
| 20110158947 | SULFONYLUREA RECEPTOR AND MEANS FOR TREATING ISCHAEMIA We disclose agents useful in the treatment of diseases or conditions that would benefit from improved muscle function and including pharmaceutical compositions and diagnostic tests for determining the predisposition of a subject, in particular a male subject, to cardiov... | 06/30/2011 |
| 20110092544 | FUNGICIDAL PYRIDINES Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein
| |
| 20100305095 | Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for... | 12/02/2010 |
| 20100286215 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION There is provided compounds of formula (I): wherein Y, ring A, D1, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptabl... | 11/11/2010 |
| 20100247439 | DENDRITIC NANO-ANTIOXIDANTS Provided are dendritic nano-antioxidant compounds according to Formula I, which may further comprise active agents covalently or non-covalently attached. Further provided are compositions comprising the disclosed compounds. Also disclosed are cosmetic compositions and d... | 09/30/2010 |
| 20100210837 | PACTAMYCIN BIOSYNTHETIC GENE CLUSTER This disclosure describes the molecular cloning of a pactamycin biosynthetic gene cluster from Streptomyces pactum ATCC 27456, characterization of individual genes in the gene cluster and the proteins encoded thereby as well as uses thereof. The pactamycin gene c... | 08/19/2010 |
| 20100204280 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE A compound of Formula, (I) or Formula: (II)... | 08/12/2010 |
| 20090221832 | PROCESS FOR PREPARING KETONES FROM ALPHA-OXO CARBOXYLATES AND ARYL BROMIDES A process for preparing ketones of the general formula (III) where
| |
| 20090197767 | PYRIDINE KETONES WITH HERBICIDAL EFFECT The invention relates to compounds of formula (I) wherein A1 is C(R1R2)p; A2 is C(R6R7)q; p is 1 or 2; q is 1 or 2; each of R1, R2, R3, R4... | 08/06/2009 |
| 20090124669 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The compounds are bioisosteres of substances with avenanthramide structures.... | 05/14/2009 |
| 20080293717 | ARYL SULFONAMIDES Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in ... | 11/27/2008 |
| 20080255364 | Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof Process for preparing unsubstituted or nuclear-substituted α-chloroalkyl pyridyl ketones and/or their hydrochlorides by reacting the corresponding unsubstituted or nuclear-substituted alkyl pyridyl ketone hydrochlorides with sulfuryl chloride at a reaction temperature ... | 10/16/2008 |
| 20080207702 | Use of Quaternary Pyridinium Salts as Vasoprotective Agents The invention relates to the use of quaternary pyridium salts of formula (1) wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or pre... | 08/28/2008 |
| 20080194627 | Aryl substituted pyridines and the use thereof This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1—R4 are set in the specification. The invention is also directed to the use of compounds... | 08/14/2008 |
| 20080096889 | Histone Deacetylases Inhibitors New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjug... | 04/24/2008 |
| 20080058315 | Integrase inhibitors Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. ... | 03/06/2008 |
| 20070299263 | Hydroxy Alkyl Amines Disclosed are compounds of formula X, which are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising compounds of formula X and methods of preparing the compounds of formula X are also disclosed. ... | 12/27/2007 |
| 20070265317 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN—COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is ... | 11/15/2007 |
| 20070213368 | N-ETHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS An N-ethyl hydroxyethyleneamine of formula (I) are disclosed which are useful in treating CNS conditions, including neurodegenerative diseases such as Alzheimer's Disease. ... | 09/13/2007 |
| 20070213311 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl... | 09/13/2007 |
| 20070203080 | New Drug Delivery System for Crossing the Blood Brain Barrier New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body. ... | 08/30/2007 |
| 20070196406 | 1,3-Dimethylbutyl carboxanilides for controlling undesirable micro-organisms This invention relates to novel 1,3-dimethylbutylcarboxanilides of the formula (I)
| 08/23/2007 |
| 20070185331 | In-situ treatment of pyridine 2,3-dicarboxylic acid esters with an oxidizing agent A method for the in-situ treatment of a pyridine-2,3-dicarboxylic acid ester with an oxidizing agent, such as hydrogen peroxide, to improve product quality is provided. The method for the in-situ removal of impurities from a saponified solution of pyridine-2,3-dicarblxy... | 08/09/2007 |
| 20070179183 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists Compounds of the following formula and salts thereof are described as integrin α4-antagonists, wherein the various symbols are as defined in the specification. ... | 08/02/2007 |
| 20070161683 | Certain chemical entities, compositions, and methods Compounds useful for treating cellular proliferative diseases are disclosed. ... | 07/12/2007 |
| 20070155969 | PROCESSES FOR THE PREPARATION OF S-(-)-AMLODIPINE Provided is a process for the preparation of S-(−)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(−)-tartaric acid. ... | 07/05/2007 |
| 20070142634 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The ... | 06/21/2007 |
| 20070135495 | Amlodipine gentisate and a method of its preparation The present invention relates to an acid salt of amlodipine gentisate and a method of its preparation. More particularly, the present invention relates to a crystalline acid salt of amlodipine gentisate of the following formula 1 prepared by reacting amlodipine and gent... | 06/14/2007 |
| 20070129335 | T-type calcium channel blocker There is provided a T-type calcium channel blocker that is a compound of formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof. wherein Ar1 is phenyl group, pyridyl group, furyl group or 2,1,3-benzoxadiazol-4-yl group; nitrog... | 06/07/2007 |
| 20070123468 | Prodrugs of active agents Disclosed herein are prodrugs of active agents which contain at least one amine, phenol, carboxylic acid, or thiol functionality. Also disclosed herein are methods of making prodrugs of active agents, pharmaceutical compositions of prodrugs of active agents and methods ... | 05/31/2007 |
| 20070117980 | MANGANESE DIOXIDE CATALYST FOR THE HYDROLYSIS OF CARBONITRILES A manganese dioxide catalyst for hydrolysing organic nitrites which bear readily oxidizable groups such as thiol or thioether groups to the corresponding carboxamides, and to a process for preparing the catalyst and to its use for hydrolysing organic nitrites. ... | 05/24/2007 |
| 20070117761 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, a... | 05/24/2007 |
| 20070099893 | Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such ... | 05/03/2007 |
| 20070099919 | Composition and synthesis of new reagents for inhibition of HIV replication The present invention provides compounds and compositions for inhibiting Vif and methods for treating viral infection, e.g., HIV infection. ... | 05/03/2007 |
| 20070093661 | Method for the enantiomoeric separation of optical active amlodipine The present invention relates to the preparation of the (S)-(−)-amlodipine and (R)-(+)-amlodipine by means of enantiomoeric separation of racemic amlodipine mixture, in which, L- or D-tartaric acid is used as resolution agent, and organic solvent containing 2-butone i... | 04/26/2007 |
| 20070093535 | Vinyl phenyl derivatives as GLK activators The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R1, R2, R3, n and m are as described in the specification, useful in the treatment of a disease or condition mediated through gluco... | 04/26/2007 |
| 20070078169 | Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, where;
| |
| 20070072916 | Amino ceramide-like compounds and therapeutic methods of use Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer syntha... | 03/29/2007 |
| 20070066658 | OPIOID RECEPTOR ANTAGONISTS A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtur... | 03/22/2007 |
